Physician profile
John F Rothrock
NPI 1174577449
$224,931.12
in general payments reported to CMS, 2019-2025
18 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $24K · 2021: $47K · 2022: $39K · 2023: $31K · 2024: $19K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Consulting Fee: $7,560 · Honoraria: $5,388 · Food and Beverage: $2,945 · Travel and Lodging: $1,748 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,325.00 |
| Consulting Fee | $7,559.75 |
| Honoraria | $5,387.50 |
| Food and Beverage | $2,945.47 |
| Travel and Lodging | $1,748.30 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80,427.39 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lundbeck LLC | $38,180.29 | 2020-2025 | Vyepti |
| Allergan, INC. | $37,894.77 | 2019-2022 | |
| Amgen INC. | $30,123.54 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $15,664.97 | 2022-2023 | Trudhesa |
| Lilly USA, LLC | $8,309.09 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $5,225.61 | 2021 | |
| Pfizer INC. | $3,638.14 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,617.74 | 2022 | |
| Supernus Pharmaceuticals, INC. | $786.93 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $500.00 | 2019 | |
| Tonix Medicines, INC. | $500.00 | 2024 | Zembrace Symtouch |
| Takeda Pharmaceuticals U.S.A., INC. | $26.28 | 2021 | |
| Boston Scientific Corporation | $19.64 | 2024 | Embold Fibered |
| Promius Pharma LLC | $16.73 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rothrock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.